Compare CDRE & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRE | SLDB |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 2017 |
| Metric | CDRE | SLDB |
|---|---|---|
| Price | $34.16 | $8.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $39.67 | $16.36 |
| AVG Volume (30 Days) | 398.7K | ★ 957.2K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | 13.33 | ★ 34.97 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $610,308,000.00 | $8,094,000.00 |
| Revenue This Year | $23.72 | N/A |
| Revenue Next Year | $6.89 | N/A |
| P/E Ratio | $109.35 | ★ N/A |
| Revenue Growth | ★ 7.53 | N/A |
| 52 Week Low | $25.73 | $3.79 |
| 52 Week High | $48.76 | $11.45 |
| Indicator | CDRE | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.73 |
| Support Level | N/A | $6.25 |
| Resistance Level | N/A | $11.45 |
| Average True Range (ATR) | 0.00 | 0.42 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 88.82 |
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments - the Product segment, which is comprised of components that manufacture and sell products, and the Distribution segment, which is comprised of business that serves as a one-stop shop for law enforcement agencies that sells goods produced by the Product segment, as well as other third-party products.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.